CEO Executive AssistantBusiness development is often the function where biotech CEOs feel most reluctant to delegate. The argument seems intuitive: partnerships, licensing deals, and M&A transactions are high-stakes, relationship-intensive activities where CEO involvement is often expected and sometimes required. A CEO who is not personally involved in business development may seem disengaged from the organization’s growth strategy.
But this reasoning conflates two very different things: the CEO’s strategic role in business development (which is irreplaceable) and the operational execution of business development activities (which should be fully delegated). This guide outlines how biotech CEOs can maintain their essential role in business development while building an operational BD function that does not depend on CEO bandwidth for its effectiveness.
The Business Development Delegation Problem in Biotech
Biotech CEOs are frequently founders or scientific co-founders who established the company’s first partnerships through personal relationships. This history can make it structurally difficult to delegate BD activities, because the CEO’s relationships are often genuine competitive advantages that cannot simply be transferred.
The problem emerges when the CEO’s continued operational involvement in BD limits the organization’s capacity to pursue the volume and variety of transactions that the pipeline requires. If the CEO must be personally involved in every BD outreach, every confidentiality agreement negotiation, and every management presentation, the pace of BD activity is constrained by one person’s bandwidth.
According to McKinsey research on biopharma leadership, the most effective biotech and pharma CEOs maintain strategic BD leadership while building operational BD organizations capable of managing a full pipeline of partnership opportunities at scale.
The CEO’s Non-Delegable BD Role
Before addressing what should be delegated, it is worth being precise about what the CEO must personally own in business development:
Strategic relationship cultivation. The CEO should maintain personal relationships with the Business Development leads and C-suite executives at the 10-15 pharmaceutical companies most likely to be partners or acquirers. These relationships are built over time, often at conferences, through joint scientific initiatives, and through personal outreach. No BD team member can substitute for this.
Deal architecture for transformational transactions. When a potential transaction is strategically transformational - a major collaboration covering multiple programs, a significant licensing deal, or an M&A transaction - the CEO must be personally engaged in the deal architecture and negotiation. This is not about managing legal documents; it is about ensuring the strategic intent of the deal is preserved through the negotiation process.
Go/no-go decisions on major transactions. The decision to pursue, structure, or walk away from a major partnership or acquisition is a CEO-level decision. The BD team provides the analysis and recommendation; the CEO makes the call.
Investor communication about BD strategy. How the company’s BD strategy is communicated to investors and the board of directors is a CEO responsibility. The CEO must be able to articulate the company’s partnership philosophy, prioritization criteria, and transaction criteria in terms that build investor confidence.
What Should Be Delegated
With the CEO’s irreplaceable BD functions defined, a substantial operational BD workload can and should be delegated:
Inbound and outbound opportunity management:
- Managing the inflow of partnership inquiries
- Initial screening and qualification of opportunities
- Responding to inbound expressions of interest
- Maintaining the company’s BD pipeline CRM
Deal process management:
- Confidentiality agreement preparation and negotiation
- Data room preparation and due diligence coordination
- Management presentation development and logistics
- Term sheet drafting and initial negotiation (with CEO review of final terms)
- Legal coordination through transaction closing
Market and competitive intelligence:
- Monitoring competitor BD transactions
- Tracking pharma company R&D investment priorities
- Identifying emerging partnership opportunity areas
- Conference intelligence gathering
Conference and relationship support:
- JPMorgan, BIO International, and other conference scheduling and logistics
- Partner meeting scheduling and briefing preparation
- Follow-up correspondence after CEO meetings
To whom: Chief Business Officer or VP of Business Development, supported by BD Directors, a Director of Alliance Management, and BD analysts.
The pharma CEO guide provides a broader framework for how pharma and biotech CEOs can structure functional delegation across the enterprise.
Building the Operational BD Organization
The quality of the delegated BD function depends entirely on the caliber of the team and the systems supporting it. For biotech CEOs investing in BD organizational infrastructure, several elements are essential:
An experienced CBO or VP of BD. The Chief Business Officer should be capable of conducting preliminary partnership conversations, representing the company credibly at BD conferences, and leading deal processes for smaller transactions independently. The CEO should not need to be involved in every BD conversation. A CBO who needs the CEO to open every door is not capable of operating the function at the required level.
A structured deal pipeline process. The BD function should maintain a structured pipeline of opportunities at different stages: monitoring, early engagement, active diligence, term sheet, and negotiation. The CEO reviews the pipeline monthly, asks questions, and makes decisions about where to invest CEO relationship capital.
An alliance management function. Once partnerships are signed, they require ongoing management - governance meetings, milestone tracking, scientific exchange facilitation, and commercial coordination. This work is fully delegable to an alliance management team. The CEO participates in senior-level partner relationships (with partner CEOs or Executive VPs) but does not manage day-to-day alliance operations.
BD analytics capability. Competitive intelligence, deal benchmarking, and financial modeling for potential transactions require dedicated analytical capability. This should be resourced within the BD team rather than outsourced to the CEO or CFO.
The CEO-BD Team Interface
The most common delegation failure in biotech BD is a poorly defined interface between the CEO’s relationship network and the BD team’s operational activities. Several practices make this interface work:
CEO relationship mapping. The CEO and CBO maintain a shared map of the CEO’s BD relationships - which pharma companies, who the relationships are with, and what strategic intent each relationship serves. The BD team uses this map to ensure their outreach activities complement rather than conflict with the CEO’s relationship network.
Briefing before and debriefing after CEO BD meetings. The BD team prepares the CEO for every major BD meeting: relevant background on the partner’s R&D priorities, status of any existing conversations, and suggested discussion objectives. After the meeting, the CEO debriefs the BD team on outcomes, so follow-up actions can be assigned and tracked.
Clear escalation criteria. The BD team knows which types of transactions require CEO involvement at each stage, and which they can advance independently. A transaction above a defined financial threshold, or involving a strategic partner of high priority, escalates to CEO engagement at the term sheet stage. A smaller licensing deal or technology access agreement may be fully managed by the CBO.
Delegating Conference BD Activities
Pharmaceutical and biotech conferences are a primary venue for BD relationship development. CEOs of biotech companies are typically expected to attend JPMorgan Healthcare Conference, BIO International Convention, and relevant disease-specific medical meetings. Managing the CEO’s conference schedule efficiently is a delegation and logistics challenge.
What to delegate:
- Conference registration and logistics
- Partnering meeting scheduling (using conference scheduling platforms)
- Meeting brief preparation for each scheduled meeting
- Coordination of company presentation logistics
- Follow-up correspondence after conference meetings
What the CEO owns: Selection of which conferences to attend, final meeting schedule review, and conducting the meetings themselves for strategic partners.
The BD team should set the CEO’s conference agenda 8-12 weeks in advance, prioritizing meetings with the highest-value potential partners. The CEO reviews and adjusts the draft agenda but does not manage the scheduling process.
Biotech IPO and M&A Readiness
For biotech companies approaching IPO or strategic acquisition conversations, the CEO’s role in BD shifts significantly. Investor relations and potential acquirer conversations become primary CEO activities.
The biotech ipo prep guide covers how biotech CEOs should structure delegation during the IPO preparation process, including how BD and IR activities intersect in the pre-IPO period.
During M&A processes, the CEO must be more operationally involved in BD activities than at other times, because the stakes of a transaction are at their highest. Even so, the BD team should manage the process - document preparation, data room management, process timeline coordination - while the CEO focuses on relationship management and deal architecture.
Common BD Delegation Failures
CEO as sole relationship holder. When all pharma partner relationships run through the CEO personally, the company is a single point of failure. Introducing BD team members into partner relationships - as meeting participants, follow-up correspondents, and relationship managers for mid-level partner relationships - distributes organizational knowledge and builds institutional relationship equity.
BD team without authority. A BD team that must escalate every substantive discussion to the CEO will move slowly and frustrate potential partners. The CBO should have authority to conduct substantive partnership conversations, share non-confidential data, and advance deals to term sheet stage for smaller transactions.
Conference overwhelm. CEOs who try to conduct 40 partnering meetings over three conference days are conducting 40 mediocre meetings. Prioritization, with the BD team’s analytical support, is the answer. Fewer, better-prepared meetings with higher-priority partners produce better outcomes.
Conclusion
Business development is one of the highest-leverage functions in a biotech company, and the CEO’s role in it is genuinely irreplaceable at the strategic level. But the operational management of BD activities - opportunity screening, deal process management, alliance management, and conference logistics - is fully delegable to a capable BD team.
Biotech CEOs who invest in building strong BD organizations, define their own non-delegable BD responsibilities precisely, and create clear interfaces between CEO relationship capital and operational BD activities will build more partnerships, close better deals, and do so at greater scale than those who try to personally manage the entire BD function.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.